About Ubiquitin carboxyl-terminal hydrolase 46
Ubiquitin carboxyl-terminal hydrolase 46 (USP46) is a protein
from Homo sapiens identified by UniProt accession
P62068, 366 residues long.
MolForge cross-references it against 0 known binders and
89 disease associations.
Target properties
| Protein name | Ubiquitin carboxyl-terminal hydrolase 46 |
| UniProt accession | P62068 |
| Gene | USP46 |
| Organism | Homo sapiens |
| Length | 366 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (89)
Diseases linked to this target (Open Targets).
- body mass index · score 0.21
- adult onset asthma · score 0.16
- platelet count · score 0.13
- major depressive disorder · score 0.08
- Asperger syndrome · score 0.05
- neoplasm · score 0.05
- dehydrated hereditary stomatocytosis · score 0.05
- Adult-onset autosomal recessive sideroblastic anemia · score 0.05
- glioblastoma multiforme · score 0.05
- Familial hemophagocytic lymphohistiocytosis · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P62068-F1 | alphafold | PREDICTED | 89.52 | — |
Amino-acid sequence (366 residues)
MTVRNIASIC NMGTNASALE KDIGPEQFPI NEHYFGLVNF GNTCYCNSVL QALYFCRPFR ENVLAYKAQQ KKKENLLTCL ADLFHSIATQ KKKVGVIPPK KFISRLRKEN DLFDNYMQQD AHEFLNYLLN TIADILQEEK KQEKQNGKLK NGNMNEPAEN NKPELTWVHE IFQGTLTNET RCLNCETVSS KDEDFLDLSV DVEQNTSITH CLRDFSNTET LCSEQKYYCE TCCSKQEAQK RMRVKKLPMI LALHLKRFKY MEQLHRYTKL SYRVVFPLEL RLFNTSSDAV NLDRMYDLVA VVVHCGSGPN RGHYITIVKS HGFWLLFDDD IVEKIDAQAI EEFYGLTSDI SKNSESGYIL FYQSRE
Explore Ubiquitin carboxyl-terminal hydrolase 46 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets